AbbVie delivered fourth-quarter 2025 results that silenced skeptics who questioned whether the pharmaceutical giant could successfully navigate the patent cliff of its former crown jewel, Humira. The company beat earnings estimates handily as newer immunology drugs Skyrizi and Rinvoq continued their remarkable growth trajectories, more than offsetting the ongoing erosion of Humira revenues from biosimilar competition.

The Illinois-based drugmaker reported adjusted earnings per share of $2.72 for the quarter, topping the $2.65 consensus estimate. Revenue came in at $16.8 billion, slightly above the $16.4 billion Wall Street had projected. Shares rose modestly in pre-market trading as investors digested what amounted to a validation of the company's strategic pivot.

The Skyrizi and Rinvoq Juggernaut

The story of AbbVie's fourth quarter—and indeed its entire 2025 fiscal year—is the story of Skyrizi and Rinvoq. These two immunology drugs, which treat conditions ranging from psoriasis to rheumatoid arthritis to Crohn's disease, generated combined revenues of $7.2 billion in Q4 alone, representing year-over-year growth of approximately 52%.

Skyrizi, the IL-23 inhibitor that has become AbbVie's fastest-growing product, contributed $4.3 billion of that total. Rinvoq, the JAK inhibitor with a broader range of approved indications, added $2.9 billion. Together, these drugs have become the foundation of AbbVie's immunology franchise and the engines of future growth.

"Skyrizi and Rinvoq are executing exactly as we planned, and in many cases exceeding our expectations. We've built a durable immunology franchise that will drive growth for the next decade."

— CEO Robert Michael, AbbVie Q4 2025 Earnings Call

Humira's Managed Decline

For nearly two decades, Humira was the world's best-selling drug, generating peak annual revenues exceeding $20 billion. The loss of U.S. patent exclusivity in January 2023 opened the door to biosimilar competition that has steadily eroded that revenue base.

In Q4 2025, Humira generated approximately $2.1 billion in revenue, down roughly 35% from the year-ago period. While substantial, this decline was actually slightly better than analysts had feared, suggesting that AbbVie's managed erosion strategy—which includes patient retention programs and strategic pricing—is working as intended.

Management guided that Humira revenues will continue declining through 2026 and beyond, eventually stabilizing at a much lower level. However, the company emphasized that Skyrizi and Rinvoq growth would more than compensate, enabling overall immunology franchise revenue to expand despite Humira's decline.

Oncology and Aesthetics Provide Diversification

Beyond immunology, AbbVie's oncology and aesthetics portfolios delivered solid performances that highlighted the company's diversification strategy:

  • Oncology: The segment generated $1.8 billion in Q4 revenue, driven by hematology drug Venclexta and newly launched assets like Elahere for ovarian cancer
  • Aesthetics: Botox and Juvederm contributed approximately $1.6 billion, with growth resuming after a challenging period of inventory normalization
  • Neuroscience: Vraylar and migraine treatment Qulipta added $1.2 billion, with both drugs gaining market share in competitive categories

This multi-pillar approach reduces AbbVie's dependence on any single product and provides multiple vectors for growth even as individual assets face patent expirations or competitive pressures.

Dividend Aristocrat Status Reinforced

AbbVie announced that its Board of Directors approved a 5.5% increase in the quarterly dividend, raising the annual payout to $6.60 per share. This marks the 53rd consecutive year of dividend increases when including the company's history as part of Abbott Laboratories—a track record that qualifies AbbVie as a Dividend Aristocrat.

The dividend increase underscores management's confidence in the company's cash flow generation and balance sheet strength. Even after accounting for approximately $9.8 billion in dividends paid during 2025, AbbVie generated substantial free cash flow that can fund continued business development and pipeline investments.

2026 Outlook

Looking ahead, AbbVie provided full-year 2026 adjusted EPS guidance of $11.95 to $12.15, representing modest growth from 2025 levels despite continued Humira erosion. Revenue guidance of $68-70 billion implies growth in the mid-single digits.

Management identified several catalysts for the coming year:

  • Continued Skyrizi and Rinvoq share gains in existing indications
  • Potential Skyrizi approval for ulcerative colitis, expanding its addressable market
  • Ongoing enrollment in late-stage oncology trials that could yield new approval opportunities
  • Strategic tuck-in acquisitions to supplement the internal pipeline

The Investment Case

AbbVie's Q4 results reinforce the thesis that the company has successfully navigated one of the most challenging patent cliffs in pharmaceutical history. While Humira's decline was inevitable, the company's preparation—investing billions in Skyrizi and Rinvoq development while diversifying into oncology, aesthetics, and neuroscience—has positioned it for sustained growth.

With a forward P/E ratio below the healthcare sector average, a dividend yield approaching 4%, and a clear growth trajectory, AbbVie offers an unusual combination of value and growth characteristics. For income-focused investors in particular, the company's 53-year dividend increase streak provides confidence in the sustainability of shareholder returns.

The pharmaceutical industry's current moment—with AI disruption fears hammering software stocks and defensive sectors gaining favor—may actually benefit stable, cash-generative names like AbbVie. In uncertain times, companies that deliver consistent earnings and growing dividends tend to outperform.